Provide feedbackProvide feedback

« Back

Kai Pharmaceuticals enters into license agreement with Ono Pharmaceutical

Monday, December 19 2011 | Comments
Evidence Grade 0 What's This?
Kai Pharmaceuticals Inc. and Ono Pharmaceutical Co. Ltd. established an agreement regarding the development and commercialization of KAI-4169, Kai's lead product candidate, in Japan.

The agreement grants Ono exclusive rights to all indications for injectable formulations of KAI-4169 in Japan. Kai retains commercialization rights elsewhere.

Pursuant to the agreement, Kai will receive an up-front payment of approximately $13 million from Ono, in addition to "significant" development, regulatory and commercialization milestone payments. Kai will also receive a royalty on sales.

An intravenous formulation of KAI-4169 is in Phase II testing as a treatment for secondary hyperparathyroidism in patients with chronic kidney disease-related mineral and bone disorder.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.